Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ G5 Entertainment: Umsatzrückgang im Q4 2025 lässt Aktie abstürzen (Investing.com DE) +++ G5 ENTERTAINMENT Aktie -28,70%

MASIMO Aktie

 >MASIMO Aktienkurs 
152 EUR    +38.3%    (TradegateBSX)
Ask: 152 EUR / 500 Stück
Bid: 146.2 EUR / 500 Stück
Tagesumsatz: 1183 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
MASIMO Aktie über LYNX handeln
>MASIMO Performance
1 Woche: -1,9%
1 Monat: -9,4%
3 Monate: -15,8%
6 Monate: -15,9%
1 Jahr: -35,8%
laufendes Jahr: -0,2%
>MASIMO Aktie
Name:  MASIMO CORP. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US5747951003 / 578074
Symbol/ Ticker:  3M4 (Frankfurt) / MASI (NASDAQ)
Kürzel:  FRA:3M4, ETR:3M4, 3M4:GR, NASDAQ:MASI
Index:  -
Webseite:  https://www.masimo.com/
Profil:  Masimo Corporation is a global leader in noninvasive monitoring technologies, specifically focusing on developing innovative medical devices that improve patient outcomes and reduce the cost of care. ..
>Volltext..
Marktkapitalisierung:  5890.17 Mio. EUR
Unternehmenswert:  6121.57 Mio. EUR
Umsatz:  1445.06 Mio. EUR
EBITDA:  193.96 Mio. EUR
Nettogewinn:  -479.75 Mio. EUR
Gewinn je Aktie:  -8.93 EUR
Schulden:  493.9 Mio. EUR
Liquide Mittel:  265.15 Mio. EUR
Operativer Cashflow:  175.08 Mio. EUR
Bargeldquote:  0.85
Umsatzwachstum:  -20.33%
Gewinnwachstum:  -786.49%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Div. Historie:  23.11.12 - 0.858€
03.12.10 - 0.692625€
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 2.555.570 USD.
Suchwörter:  MASIMO
Letzte Datenerhebung:  17.02.26
>MASIMO Kennzahlen
Aktien/ Unternehmen:
Aktien: 53.71 Mio. St.
Frei handelbar: 93.59%
Rückkaufquote: 1.62%
Mitarbeiter: 9200
Umsatz/Mitarb.: 0.19 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 43.72%
Bewertung:
KGV: -
KGV lG: 23.46
KUV: 4.23
KBV: 8.45
PEG-Ratio: -
EV/EBITDA: 31.56
Rentabilität:
Bruttomarge: 54.96%
Gewinnmarge: -11.88%
Operative Marge: 10.16%
Managementeffizenz:
Gesamtkaprendite: -8.31%
Eigenkaprendite: -17.93%
>MASIMO Peer Group
Gesundheit
 
17.02.26 - 06:54
Danaher nears $10B acquisition of medical tech company Masimo, FT reports (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.02.26 - 06:51
Danaher closes in on nearly $10 billion deal for Masimo, FT reports (Reuters EN)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
17.02.26 - 05:27
Danaher nears $10 bln deal to buy med tech firm Masimo- FT (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
12.02.26 - 15:03
Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26 (Business Wire)
 
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call or the webcast, please use the link below. Upon registering, each participant will be provided with details for the call or webcast. Conference Call Registration Link (Please register to obtain the dial-in number): Masimo 4Q 2025 Earnings Call A replay will be available shortly after the conclusion of the call and will be archived on the Company's website. About Masimo Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologie...
04.02.26 - 20:30
Here′s Why You Should Add Masimo Stock to Your Portfolio Now (Zacks)
 
MASI targets 7%-10% revenue growth through 2028, sharp margin expansion and rising cash flow as intelligent monitoring and partnerships gain traction....
31.01.26 - 05:01
Insiderhandel: EVP, Ops & Clinical Research verkauft Aktien von Masimo im Wert von 2555570 USD (Insiderkauf)
 
Sampath, Anand - Vorstand - Tag der Transaktion: 2026-01-28...
27.01.26 - 19:45
Why Masimo (MASI) is Poised to Beat Earnings Estimates Again (Zacks)
 
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....
15.01.26 - 18:15
Masimo Stock Declines Despite Solid Preliminary Q4 Revenues (Zacks)
 
MASI posts strong fourth-quarter and full-year 2025 preliminary results with revenue and EPS above estimates, driven by core healthcare momentum....
12.01.26 - 16:24
Masimo Posts Preliminary Q4, FY25 Results (AFX)
 
WASHINGTON (dpa-AFX) - Masimo Corporation (MASI) on Monday shared preliminary figures for the fourth quarter and full year ending January 3, 2026, showing solid growth in its hospital monitoring s......
05.01.26 - 20:30
Here′s Why You Should Retain Masimo Stock in Your Portfolio Now (Zacks)
 
MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks linger....
04.01.26 - 14:15
Weekend Round-Up: TSMC′s US Export Approval, Masimo′s Quality Concerns And Apple′s Vision Pro Woes (Benzinga)
 
The week highlights key tech developments, including Taiwan Semiconductor securing a one-year U.S. export license for China operations, Masimo's quality concerns despite a major patent win over Apple, OpenAI shifting AI hardware manufacturing to Foxconn, and Apple scaling back Vision Pro production after weak sales. read more...
04.01.26 - 13:27
Apple′s Vision Pro Production Plans, Masimo′s Quality Score Declines Despite Patent Win, And More: This Week In Appleverse (Benzinga)
 
Mixed bag of news for Apple as Masimo tumbles in quality despite patent win, on-device AI threatens data centers, and the Tim Cook-led company scales back Vision Pro production. read more...
02.01.26 - 13:36
Apple′s Rival Masimo Tumbles In Quality Despite $634 Million Patent Win Over iPhone-Maker (Benzinga)
 
Despite a $634M patent win over Apple, Masimo's Quality score sinks to 10.43. See why fundamentals are lagging in our latest analysis. read more...
30.12.25 - 15:00
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium (Zacks)
 
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo....
26.12.25 - 17:30
Why Masimo (MASI) is a Top Growth Stock for the Long-Term (Zacks)
 
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....
10.12.25 - 17:30
Masimo (MASI) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
 
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....
05.12.25 - 21:21
HALPER SADEH LLC ENCOURAGES MASIMO CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
 
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Masimo Corporation (NASDAQ: MASI) breached......
04.12.25 - 04:42
Masimo Outlines Long-term Strategy (AFX)
 
WASHINGTON (dpa-AFX) - Masimo (MASI) hosted its 2025 Investor Day at the company's headquarters, where management outlined its long-term strategy.The company's updated long-range plan through 2028......
28.11.25 - 01:00
Masimo (MASI) Q3 2025 Earnings Call Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
24.11.25 - 20:30
Masimo (MASI) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
 
Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein Vamp lebt vom Verkauf der Gefühle. - Dr. Fritz P. Rinnhofer
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!